Epigenetic concerns in therapy for Chronic Obstructive Pulmonary Disease

Nagaraju Inturi\textsuperscript{1}, Sunithasree Cheweti\textsuperscript{2}, Kwang-Hoon Oh\textsuperscript{3}, Arun Kumar Sanapala\textsuperscript{4}, Sunil Junapudi\textsuperscript{5*} and Viajaya Nirmala Pangi\textsuperscript{6*}

\textsuperscript{1}Department of Bioinformatics, Teesside University, Middlesbrough, UK
\textsuperscript{2}Hindu College of Pharmacy, Nagarjuna University, Guntur-522002, Andhrapradesh, India
\textsuperscript{3}Department of Physical Education, Kongju National University, Chungcheongnam-do- 314701, South Korea
\textsuperscript{4}Department of Pharmacology, Sree Daattha Institute of Pharmacy, Sherriguda, India
\textsuperscript{5}Associate Professor, Department of Pharmaceutical Chemistry, Geethanjali College of Pharmac, Cherryal, Keesara, India
\textsuperscript{6}Assistant Professor, Head of the Department, School of Life and Health Sciences Adikavi Nannaya University, India

*Corresponding author: Sunil Junapudi, Associate Professor, Department of Pharmaceutical Chemistry, Geethanjali College of Pharmac, Cherryal, Keesara, Medchalmalkajgiri-501301, Telangana, India

\textsuperscript{6}Viajaya Nirmala Pangi, Assistant Professor, Head of the Department, School of Life and Health Sciences, Adikavi Nannaya University, Rajahmundry-533296, Andhra Pradesh, India

ARTICLE INFO

Received: \textsuperscript{6}July 04, 2021
Published: \textsuperscript{6}July 16, 2021

Citation: Nagaraju Inturi, Sunithasree Cheweti, Kwang-Hoon Oh, Arun Kumar Sanapala, Sunil Junapudi, Viajaya Nirmala Pangi. Epigenetic concerns in therapy for Chronic Obstructive Pulmonary Disease. Biomed J Sci & Tech Res 37(2)-2021. BJSTR. MS.ID.005971.

Keywords: COPD; DNA Methylation; Epigenetic; Histone

ABSTRACT

Many multifaceted diseases, the complexity of which we are just beginning to understand and supposed to include epigenetic pathways. Chronic obstructive pulmonary disorder (COPD) and asthma are two respiratory diseases risk with influential environmental factors depending on the underlying inherited vulnerability. Via the modulation of ecological effects to regulate disease development, epigenetic mechanisms such as histone modification, methylation of DNA, and miRNA can be concerned in these processes. Because of their proven modifiability, epigenetic mechanisms open up new opportunities for clinical interference. In this review, we summarised an overview of respiratory epigenetics for COPD, which is the relevance of our existing awareness of mechanisms that lead to these diseases. We also emphasized the epigenetic studies of heritable phenotype changes and the involvement in DNA sequence alterations.

Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; DNMT: DNA Methyltransferase; CPG: Cytosine Phosphate Guanine; CS: Cigarette Smoking

Introduction

COPD (Chronic Obstructive Pulmonary Disease) is a prevalent chronic adult disease that, by 2020, will be the world’s 3rd leading cause of death. COPD is characterized by mucociliary dysfunction, lung inflammation, airway fibrosis, and alveolar destruction [1]. There are many factors at hand, such as chronic inflammation, the theory of elastase/anti-elastase, apoptosis, the balance of oxidant-antioxidant, and infective repair that cause COPD pathogenesis [2,3]. Cigarette smoke contains over 4700 organic compounds and 1014 free radicals/oxidants, making it the primary source of COPD and inflammation [4]. It stimulates multiple redox-sensitive transcription factors such as NF-kB (nuclear factor kappa-B), most important to increased pro-inflammatory cytokine and chemokine assembly in COPD [5,6]. Post-translational changes in histone and other DNA proteins are known as epigenetic alterations [7]. Without altering the primary gene sequence, DNA methylation and histone methylation can influence gene expression such as post-translational histone protein modifications are acetylation, phosphorylation, and ubiquitination (H2A, H2B, H3, and H4) [8].
Methylation of DNA, which is catalyzed by DNA methyltransferase (DNMT) family members, is an essential epigenetic process that attaches methyl groups to cytosine residues in Cytosine Phosphate-Guanine (CpG) [9,10]. Hypermethylation of DNA in CpG island gene promoter regions results in gene silencing, while hypomethylation results in DNA transcription activation [9]. Histones are essential protein components of chromatin. Chromatin consists of H-linker and octamer protein containing two copies of each H2A, H2B, H3, and H4 core histone where DNA is wrapped [11]. H3K4me3, H3K9me3, and H3K27me3 are modifications of histones that play a significant role in controlling genes. The activation of gene expression with H3K4me3, but gene expression is associated with H3K27me3 and H3K9me3 [11].

**DNA Modification in COPD**

The same DNA sequence can be found in all of an organism’s cells. Thus, with the aid of epigenetic control, the genome is organized into ‘heterochromatin’ (compact) and ‘euchromatin’ (accessible) regions to ensure the right transcriptional program in a particular cell type. Changes in DNA alteration may explain some of the considerable variations in smokers’ vulnerability to developing COPD. Indeed, 349 Cytosine phosphate Guanine (CpG) sites were confirmed to be significantly associated with the intensity of COPD and the reduction in lung function by large-scale genome-wide investigations of DNA methylation marks (27,000 genes) [12]. Cigarette smoking (CS) condensate can cause multiple CpG targets in small human airways and bronchial epithelial cells to hypo or hypermethylation [13]. Changes in DNA methylation patterns have been found to enhance histopathology based on the experiment carried out on mice for smoke exposure. Similarly, DNA methylation caused by various dangerous elements may increase the sensitivity of COPD to a subsequent insult. This is confirmed by the transparency of pre-birth cigarette smoke affects explicit CpG DNA methylation in detoxification characteristics worldwide and performance. This also leads to constant effects, such as decreased lung work in young people [14,15].

This subject has only been marginally debated about lung cancer, but not concerning COPD. CS exposed human bronchial epithelial cells had lower levels of DNMT1 and higher levels of DNMT3b [13]. On the other hand, CS elevated DNMT1 levels in A549 cells, while DNMT3b downregulation triggered synuclein-gamma demethylation, a prometastatic oncogene. DNMT1, DNMT3a, and DNMT3b proteins are significantly elevated in patients with lung tumors [17]. In addition, nitrosamine ketone (NNK) obtained from tobacco-specific carcinogenic nicotine-induced nucleus aggregation of DNMT1, accompanied by hypermethylation of the tumor suppressor gene in mice and lung cancer patients who regularly smoked [13]. Polycomb group (PcG) proteins were discovered for the first time in Drosophila melanogaster, and they represent a novel epigenetic control region. The Polycomb target gene RUNX3, a tumor suppressor gene, is associated with promoter methylation and CS [18]. Besides, it has been demonstrated that CS condensate silences tumor suppressor miRNA, miR-487b expression epigenetically. In lung epithelial and lung cancer cells following CS treatment, PRC-mediated DNA methylation and altered nucleosome location within the miR-487b region were observed [19].

**DNA Methylation and COPD**

![Figure 1: The main ways of modifying epigenetics. DNA methylation, histone methylation are involved in most epigenetic modifications. The action of DNA methyltransferases can regulate DNA methylation (DNMT). Modifications of histones are mainly expressed in acetylation. Mediated by histone methyltransferases (HMTs) and histone demethylase (HDMs), and histone deacetylases (HDACs).](image-url)
DNA methylation is revealed to play a critical function in the existence and output of COPD; CS modifies the DNA methylation by triggering inflammatory responses and causing diseases such as COPD [12]. Macrophages are innate immune cells that directly affect the polarization of innate and adaptive immunity and eliminate by lung macrophages of bacteria [20]. Usually, COPD arises with upper lobe predominance, and tests have demonstrated anatomical variation in ventilation and oxygenation of the upper and lower lung lobes [21]. The main ways of modifying epigenetics DNA methylation shows in (Figures 1 & 2).

**Targeting DNA Alteration for COPD Therapy**

In COPD, DNA changes are observed by replacing cytidine within the DNA strain. Nucleoside analogs such as 5-aza-2-deoxycytidine and 5-azacytidine act as DNMT inhibitors. Most of the substrate analogs are, modified by DNMTs analogs through covalent binding, which then inhibits the functioning of enzymes, resulting in hypomethylation of DNA. The PRC2 methylation binding sites are altered or reversed using azacitidine, resulting in (5-azacytidine) non-metastatic status [22].

**Histone Modifications**

Histone modifications were grouped into eight categories based on the type of amino acid and modified into methylation, acetylation of arginine, acetylation of lysine, ADP ribosylation, threonine phosphorylation, proline isomerization, arginine deamination, sumoylation, and ubiquitination [23,24]. The induction of a double-strand break at the DNA damage foci, histone acetylation, and methylation plays an essential role in the DNA damage response. Histone H3K9 and H3K56 acetylation and H3K4 and H3K36 trimethylation have been related to active gene transcription (euchromatin). In contrast, histone H3K9 and H3K27 tri-methylation have been linked to silence gene loci (heterochromatin) due to the closure of active chromatin in the gene [25-28].

**Role of Histone Methylation in COPD**

The modulation of histones is much more significant than DNA methylation. A recent mass spectrometry technique has identified possible novel histone marks in smoke-exposed mouse lungs, including acetylation, mono-methylation, and di-methylation of specific lysine and arginine residues of histones H3 and H4 [29]. Histone H3K27me2 and H3K27me1 were only found in the CS sensitivity community. These findings suggest that Polycomb plays a role in specific gene repression, particularly after smoking [29].

**COPD Treatment Based on Histone Modifications**

In patients with COPD, effective anti-inflammatory tested by treating with inhaled or systemic corticosteroids. However, even massive doses of corticosteroids showed an immune response in COPD patients. Impaired Histone Deacetylases (HDAC) function has recently been analyzed in-depth as one of the pathways contributing to corticosteroid tolerance. The activity of HATs was inhibited by activating Glucocorticoid Receptors (GR) which binds to the co-activators (Histone Acetyltransferase) [30,31]. Theophylline has been used for decades to treat airway conditions and was recently discovered as an activator of HDAC. In COPD patients alveolar macrophages, theophylline restores HDAC activity and steroid response [32]. In CS-exposed mice, a low dose of theophylline increased the anti-inflammatory effects of dexamethasone while...
also restoring HDAC2 movement [32]. The pharmacological activation by a small molecule activator, sulforaphane, of the antioxidant NRF2 can be a valuable technique for preventing and treating COPD and is currently being tested in patients with COPD in phase II clinical trials [33].

By deacetylating lysine residues that would or else be targeted for ubiquitin-mediated proteosomal degradation, functional HDAC2 is likely to inhibit NRF2 degradation [34]. In peripheral lung tissues and alveolar macrophages, HDAC2 activation was shown to be lower in patients with COPD when the enzyme was S-nitrosylated. Treatment with sulforaphane nitrosylated HDAC2 resulted in simultaneous activation of NRF2 and augmented intracellular glutathione levels in alveolar macrophages [35].

**Conclusion**

Dysregulation of DNA methylation in COPD-related genes, HDAC2 function, and miRNAs have all been shown to cause COPD disease in various studies. Inflammatory reactions are triggered by tobacco smoke and are a central factor in COPD development. It changes epigenetic operations such as gene expression by modifying DNA methylation, altering HDAC2 function by histone modifications, and dysregulation of COPD linked to mRNAs. Our review emphasizes the recent studies of specific techniques, such as Sirtuins, to control the activity of HDAC2 and have a therapeutic effect on COPD. The miRNAs have been shown to decrease COPD in more recent research. Finally, this review can address or help study a greater variety of issues in both diagnosis and treatment methods for COPD.

**References**

1. Vestbo J, Hurd SS (2012) Rodriguez-Roisin R. The 2011 revision of the global strategy for diagnosing, managing, and preventing COPD (GOLD) why and what? The clinical respiratory journal 6(4): 208-214.

2. Shapiro SD, Ingenito EP (2005) The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. American journal of respiratory cell and molecular biology 32(5): 367-372.

3. Barnes PJ (2021) Endo-phenotyping of COPD patients. Expert Review of Respiratory Medicine 15(1): 27-37.

4. Pandey R, Singh M, Singhal U, Gupta KR, Aggarwal SK (2013) Oxidative/nitrosative stress and the pathobiology of chronic obstructive pulmonary disease. Journal of clinical and diagnostic research 7(3): 580-588.

5. Rahman I (2005) Oxidative stress in the pathogenesis of chronic obstructive pulmonary disease. Cell biology and biochemistry 43(1): 167-188.

6. Rahman I, Adcock IM (2006) Oxidative stress and redox regulation of lung inflammation in COPD. European respiratory journal 28(1): 219-242.

7. Adcock IM, Ford P, Ito K, Barnes PJ (2006) Epigenetics and airways disease. Respiratory research 7(1): 1-9.

8. Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. Cell 128(4): 707-719.

9. Yang IV, Schwartz DA (2011) Epigenetic control of gene expression in the lung. American journal of respiratory and critical care medicine 183(10): 1295-1301.

10. Azəni S, Jafari N, Javan MR, Karmi J, Ahmadi M (2017) Epigenetic modifications and therapy in multiple sclerosis. Neuromolecular medicine 19(1): 11-23.

11. Wu DD, Song J, Bartel S, Krauss-Etschmann S, Rotz MG, et al. (2018) The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach. Pharmacology & therapeutics 182: 1-4.

12. Qiu W, Baccarini A, Carey VJ, Routaou N, Bacherman H, et al. (2012) Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. American journal of respiratory and critical care medicine 185(4): 373-381.

13. Liu F, Killian JK, Yang M, Walker RL, Hong JA, et al. (2010) Epigenetic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 29(25): 3650-3664.

14. Breton CV, Byun HM, Wente M, Pan E, Yang A (2009) Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. American journal of respiratory and critical care medicine 180(5): 462-467.

15. Tessema M, Tasnew DD, Yingling CM, Do K, Petch MA, et al. (2020) Identification of novel epigenetic abnormalities as spumum biomarkers for lung cancer risk among smokers and COPD patients. Lung Cancer 146: 189-196.

16. Georgiou E, Valeri R, Tzimagiorgis G, Anzel J, Krikidis D, et al. (2007) Averant p16 promoter methylation among Greek lung cancer patients and smokers: correlation with smoking. European Journal of Cancer Prevention 16(5): 396-402.

17. Song Q, Chen P, Liu XM (2021) The role of cigarette smoke-induced pulmonary vascular endothelial cell apoptosis in COPD. Respiratory Research 22(1): 1-5.

18. Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, et al. (2008) RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer research 68(15): 6208-6214.

19. Xi S, Xu H, Shan J, Tao Y, Hong JA, et al. (2013) Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. The Journal of clinical investigation 123(3): 1241-1261.

20. Brascia EM, Bonfield TL (2016) Cystic fibrosis lung immunity: the role of the macrophage. Journal of innate immunity 8(6): 550-563.

21. West JB (1962) Regional differences in gas exchange in the lung of erect man. Journal of Applied Physiology 17(6): 893-898.

22. Hascher A, Haase AK, Hebestreit K, Rohde C, Klein HU, et al. (2014) DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clinical Cancer Research 20(4): 814-826.

23. Rando OJ, Chang HY (2009) Genome-wide views of chromatin structure. Annual review of biochemistry 78: 245-271.

24. Young NL, DiMaggio PA, Garcia BA (2010) The significance, development, and progress of high-throughput combinatorial histone code analysis. Cellular and molecular life sciences 67(23): 3983-4000.

25. Lukas J, Lukas C, Bartek J (2011) More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nature cell biology 13(10): 1161-1169.

26. Rodriguez Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nature medicine 17(3): 330-339.

27. Seligson DB, Horvath S, McInran MA, Mah V, Yu H, et al. (2009) Global levels of histone modifications predict prognosis in different cancers. The American journal of pathology 174(5): 1619-1628.

28. Zhang L, Valizadeh H, Alipourfard I, Bidkares R, Aghabati-Maleki L (2020) Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review. COPD: Journal of Chronic Obstructive Pulmonary Disease 17(3): 333-342.

Copyright@ Sunil Junapudi, Viajaya Nirmala Pangi | Biomed J Sci & Tech Res | BJSTR. MS.ID.005971.
29. Sundar IK, Nevid MZ, Friedman AE, Rahman I (2014) Cigarette smoke induces distinct histone modifications in lung cells: implications for COPD and lung cancer pathogenesis. Journal of proteome research 13(2):982-996.

30. Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. The Lancet 373(9678): 1905-1917.

31. Barnes PJ (2013) Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology 131(3): 636-645.

32. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, et al. (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. The Journal of experimental medicine 200(5): 689-95.

33. HY Cho, SR Kleeberger (2010) “Nrf2 protect against airway disorders.” Toxicology and Applied Pharmacology 224(1): 43-56.

34. Mercado N, Thimmulappa R, Thomas CM, Fenwick PS, Chana KK, et al. (2011) Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochemical and biophysical research communications 406(2): 292-298.

35. Malhotra D, Thimmulappa RK, Mercado N, Ito K, Kombairaju P, et al. (2011) Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. The Journal of clinical investigation 121(11): 4289-4302.

ISSN: 2574-1241
DOI: 10.26717/BJSTR.2021.37.005971
Sunil Junapudi, Viajaya Nirmala Pangi. Biomed J Sci & Tech Res

This work is licensed under Creative Commons Attribution 4.0 License
Submission Link: https://biomedres.us/submit-manuscript.php

Assets of Publishing with us
- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

https://biomedres.us/